COMPARISON

CJC-1295 vs Terlipressin

3 attributes held for at least one of the two. 2 differ. Each value carries the register it came from and the date that register was read.

Answer

CJC-1295 is authorised or registered in 0 and Terlipressin in 8 of the 10 registers read. CJC-1295: No trial states a phase. Terlipressin: highest phase Phase 3 (2 phase 3 trials, 0 with posted results). 0 registered trials include both.

States no view on which is preferable, safer or more effective. Not medical advice.

CJC-1295Terlipressin
Registered trials
differs
1
clinicaltrials.gov · 2026-10-03
118
clinicaltrials.gov · 2026-10-03
FDA label
differs
Not checked
no record of "fdaLabel" for cjc-1295
FDA-approved: Terlivaz
openfda · 2026-10-03T17:23:44.062Z
EU authorisation
Nothing on record
ema read 2026-08-31
Nothing on record
ema read 2026-08-31

SIDE EFFECTS

Most common side effects, each beside its own placebo

Side effectCJC-1295placeboTerlipressinplacebo
Abdominal pain--21.8%13.4%
Diarrhoea--16.4%5.7%
Nausea--15.0%11.3%
Dyspnoea--12.3%6.7%
Hypotension--11.3%6.7%
Respiratory failure--10.5%3.0%
Vomiting--8.9%7.2%
Hypokalaemia--8.9%6.2%
Hepatic encephalopathy--8.5%11.3%
Fluid overload--8.2%4.1%

Trial register CJC-1295: 0 placebo-controlled trials; Terlipressin: 2. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. CJC-1295 side effects · Terlipressin side effects

LEGAL STATUS

Approval in each country read

CountryCJC-1295TerlipressinRegister
United StatesNot on the registerFDA-approvedRegulator FDA
European UnionNot on the registerNot on the registerRegulator EMA
United KingdomNot on the registerAuthorisedRegulator MHRA
CanadaNot on the registerNot on the registerRegulator Health Canada
AustraliaStatus unknownRegistered TGA
SwitzerlandNot on the registerAuthorisedRegulator Swissmedic
BrazilNot on the registerRegistadoRegulator ANVISA
SerbiaNot on the registerAuthorisedRegulator ALIMS
SingaporeNot on the registerRegisteredRegulator HSA
TurkeyNot on the registerRuhsatliRegulator TITCK

Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.

WEEKLY

Register Watch, weekly

New trials, approvals and enforcement actions. One email a week.